dc.contributor.author | Pesapane, F | en_US |
dc.contributor.author | Downey, K | en_US |
dc.contributor.author | Rotili, A | en_US |
dc.contributor.author | Cassano, E | en_US |
dc.contributor.author | Koh, D-M | en_US |
dc.date.accessioned | 2020-07-17T10:02:29Z | |
dc.date.issued | 2020-06-16 | |
dc.identifier.citation | Insights into imaging, 2020, 11 (1), pp. 79 - ? | |
dc.identifier.issn | 1869-4101 | |
dc.identifier.uri | https://repository.icr.ac.uk/handle/internal/3849 | |
dc.identifier.eissn | 1869-4101 | |
dc.identifier.doi | 10.1186/s13244-020-00885-4 | |
dc.description.abstract | Numerous imaging modalities may be used for the staging of women with advanced breast cancer. Although bone scintigraphy and multiplanar-CT are the most frequently used tests, others including PET, MRI and hybrid scans are also utilised, with no specific recommendations of which test should be preferentially used. We review the evidence behind the imaging modalities that characterise metastases in breast cancer and to update the evidence on comparative imaging accuracy. | |
dc.format | Electronic | |
dc.format.extent | 79 - ? | |
dc.language | eng | |
dc.language.iso | eng | |
dc.rights.uri | https://creativecommons.org/licenses/by/4.0 | |
dc.title | Imaging diagnosis of metastatic breast cancer. | |
dc.type | Journal Article | |
dcterms.dateAccepted | 2020-05-22 | |
rioxxterms.versionofrecord | 10.1186/s13244-020-00885-4 | |
rioxxterms.licenseref.uri | https://creativecommons.org/licenses/by/4.0 | |
rioxxterms.licenseref.startdate | 2020-06-16 | |
rioxxterms.type | Journal Article/Review | |
dc.relation.isPartOf | Insights into imaging | |
pubs.issue | 1 | |
pubs.notes | Not known | |
pubs.organisational-group | /ICR | |
pubs.organisational-group | /ICR/Primary Group | |
pubs.organisational-group | /ICR/Primary Group/Royal Marsden Clinical Units | |
pubs.publication-status | Published | |
pubs.volume | 11 | en_US |
pubs.embargo.terms | Not known | |
dc.contributor.icrauthor | Koh, Dow-Mu | |